首頁 > 市場調查報告書 > 製藥

藥物開發

市場調查報告書

商品編碼

1454741

體外毒理學測試市場 - 產品和服務、終點和測試、技術、方法、產業 - 全球預測，2024 年 - 2032 年

In-vitro Toxicology Testing Market - Product and Services, Endpoint and Test, Technology, Method, Industry - Global Forecast, 2024 - 2032

出版日期: 2024年02月07日 | 出版商:

Global Market Insights Inc. | 英文 270 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計從 2024 年到 2032 年，體外毒理學測試市場規模將以超過 7.7% 的CAGR成長，這主要是由於出於倫理問題和監管壓力，擴大採用體外方法而不是動物測試。人們越來越認知到化學物質對人類健康的不利影響，以及細胞培養技術的發展，正在加速體外測試的吸引力。

近年來，藥品、化妝品和化學品等各行業的藥物開發和化學品風險評估過程中的安全性評估越來越受到重視。毒理學研究資金的可用性和高通量篩選分析的開發將進一步提高體外毒理學測試解決方案的使用率。例如，2023 年 8 月，Altis Biosystems 推出了 RepliGut(R) Planar InflammaScreen(TM) 服務，利用人源體外結腸發炎模型來增強發炎性腸道疾病 (IBD) 的藥物發現。

體外毒理學測試產業分為產品和服務、終點和測試、技術、方法、產業和地區。

在產品和服務方面，由於對高通量篩選分析的需求不斷增加，從2024年到2032年，分析領域的市場規模將以8%的成長率成長。檢測技術的不斷進步使得結果更加準確可靠。人們越來越關注開發針對特定毒理學終點的專門測定方法，這將增加體外測試的滲透率。針對不同應用客製化的各種檢測試劑盒和服務的可用性也將推動該細分市場的成長。

在終點和測試方面，預計從 2024 年到 2032 年，基因毒性領域的體外毒理學測試行業將以 8% 的CAGR成長。這是由於基因毒性測試方法的進步、各個領域對基因毒性化合物的監管審查力度加大。行業，以及人們對與遺傳毒性物質相關的潛在危害的認知不斷增強。用於評估遺傳毒性的新測定方法和測試策略的開發也將增加對遺傳毒性測試中體外測試的需求。

從地區來看，亞太地區體外毒理學測試市場在預計時間內將呈現 8.2% 的成長率。這可以歸因於工業化程度的不斷提高、人們對毒性測試在藥物開發和化學品安全評估中的重要性的認知不斷提高，以及嚴格的產品安全監管指南。製藥和生物技術領域不斷成長的研發活動以及不斷擴大的醫療基礎設施將刺激該地區體外毒理學測試解決方案的採用。

產業生態系統分析
產業影響力
- 成長動力
  - 政府對毒理學研究的資助增加
  - 增加研發投入
  - 技術進步
  - 對動物實驗的抵制日益增加
- 產業陷阱與挑戰
  - 嚴格的監管限制
  - 缺乏研究複雜終點的體外模型
成長潛力分析
技術景觀
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品和服務分類，2018 年 - 2032 年

主要趨勢
耗材
化驗
- 細菌毒性測定
- 酶毒性測定
- 基於細胞的 ELISA 和蛋白質印跡
- 受體結合測定
- 組織培養測定
- 其他檢測
裝置
軟體
服務

第 6 章：市場估計與預測：按端點和測試，2018 年 - 2032 年

主要趨勢
吸收、分佈、代謝和排泄 (ADME)
皮膚刺激、腐蝕、致敏
遺傳毒性
細胞毒性
眼部毒性
器官毒性
光毒性
皮膚毒性
其他終點和測試

第 7 章：市場估計與預測：按技術分類，2018 年 - 2032 年

主要趨勢
細胞培養
高通量
毒理基因組學

第 8 章：市場估計與預測：依方法，2018 - 2032

主要趨勢
細胞檢測
生化檢測
電腦模型
離體模型

第 9 章：市場估計與預測：按產業分類，2018 年 - 2032 年

主要趨勢
藥品和生物製藥
化妝品及家居用品
食物
化學品

第 10 章：市場估計與預測：按地區，2018 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Abbott Laboratories
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Catalent, Inc.
Charles River Laboratories International, Inc.
Danaher Corporation
Eurofins Scientific
Evotec S.E.
Laboratory Corporation of America Holdings
Merck KGaA
Quest Diagnostics Incorporated
SGS Societe Generale de Surveillance SA
Thermo Fisher Scientific Inc.

簡介目錄

Product Code: 5543

In-vitro Toxicology Testing Market size is predicted to expand at over 7.7% CAGR from 2024 to 2032, mainly led by the increasing adoption of in-vitro methods over animal testing due to ethical concerns and regulatory pressures. The rising awareness about the adverse effects of chemicals on human health and the developments in cell culture technologies are accelerating the appeal of in-vitro testing.

Lately, there has been growing emphasis on safety assessment during drug development and chemical risk assessment in various industries, such as pharmaceuticals, cosmetics, and chemicals. The availability of funding for research in toxicology and the development of high-throughput screening assays will further increase the utilization of in-vitro toxicology testing solutions. For instance, in August 2023, Altis Biosystems launched RepliGut(R) Planar InflammaScreen(TM) Services to enhance drug discovery for inflammatory bowel diseases (IBD) using a human-derived in vitro model of colon inflammation.

The in-vitro toxicology testing industry is segregated into product and services, endpoint and test, technology, method, industry, and region.

With respect to product and services, the market size from the assays segment will rise at 8% growth rate from 2024 to 2032, on account of the increasing demand for high-throughput screening assays. Rising advancements in assay technologies are allowing for more accurate and reliable results. The growing focus on developing specialized assays for specific toxicological endpoints will increase the penetration of in-vitro testing. The availability of a wide range of assay kits and services tailored to different applications will also drive the segment growth.

In terms of endpoint and test, the in-vitro toxicology testing industry from the genotoxicity segment is anticipated to rise at 8% CAGR from 2024 to 2032. This is due to the advancements in genotoxicity testing methods, increased regulatory scrutiny on genotoxic compounds in various industries, and the growing awareness about the potential hazards associated with genotoxic substances. The development of novel assays and testing strategies for assessing genotoxicity will also increase the demand for in-vitro testing in genotoxicity testing.

Regionally, the Asia Pacific in-vitro toxicology testing market will depict 8.2% growth rate during the projected timeframe. This can be attributed to the increasing industrialization, rising awareness about the importance of toxicity testing in drug development and chemical safety assessment, as well as stringent regulatory guidelines for product safety. The growing R&D activities in pharmaceutical and biotechnology sectors along with the expanding healthcare infrastructure will stimulate the adoption for in-vitro toxicology testing solutions in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rise in government funding for toxicology research
  - 3.2.1.2 Increased R&D investments
  - 3.2.1.3 Technological advancements
  - 3.2.1.4 Growing resistance against animal testing
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory restrictions
  - 3.2.2.2 Lack of in-vitro models to study complex end-points
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Services, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Consumables
5.3 Assays
- 5.3.1 Bacterial toxicity assays
- 5.3.2 Enzyme toxicity assays
- 5.3.3 Cell-based ELISA and western blots
- 5.3.4 Receptor binding assays
- 5.3.5 Tissue culture assays
- 5.3.6 Others assays
5.4 Equipment
5.5 Software
5.6 Services

Chapter 6 Market Estimates and Forecast, By Endpoint and Test, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Absorption, distribution, metabolism, and excretion (ADME)
6.3 Skin irritation, corrosion, sensitization
6.4 Genotoxicity
6.5 Cytotoxicity
6.6 Ocular toxicity
6.7 Organ toxicity
6.8 Phototoxicity
6.9 Dermal toxicity
6.10 Other endpoints and tests

Chapter 7 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Cell culture
7.3 High throughput
7.4 Toxicogenomics

Chapter 8 Market Estimates and Forecast, By Method, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 Cellular assays
9.3 Biochemical assays
9.4 In silico models
9.5 Ex vivo models

Chapter 9 Market Estimates and Forecast, By Industry, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceuticals and biopharmaceuticals
8.3 Cosmetics and household products
8.4 Food
8.5 Chemicals

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa